Shanghai Junshi Bioscience Co., Ltd.

This study tests whether JS107 works better than standard treatments for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has not responded to at least one prior therapy. About 560 participants will be randomly assigned to…

This study tests a new drug called JS212, given together with other cancer medicines, in people whose colorectal cancer has spread and has not been treated before. The goal is to see if the combination is safe and can shrink tumors. About 80 adults will take part.

This study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help tumors grow. It is given alone or with another drug (JS004 or docetaxel) to 66 adults with advanced non-small cell lung cancer that got worse after standard chemotherapy and immunothera…

This study tests two experimental drugs, JS212 and JS213, alone or together, in people with advanced solid tumors like kidney, prostate, bladder cancer, or melanoma. The goal is to see if they can shrink tumors and control the disease. About 480 adults will take part to check saf…

This study tests two new drug combinations for people with advanced triple-negative breast cancer that has come back or spread. About 80 adults aged 18-75 who have not had prior treatment for advanced disease will receive either JS207 plus 9MW2821 or JS207 plus albumin paclitaxel…

This phase 2 study tests a new combination therapy called JS212 in 280 people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors or slow cancer growth. Participants must not have ha…